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Background
Uveitis is a common extra-articular feature in juvenile
idiopathic arthritis (JIA), particularly in female patients
with the extended oligoarticular subtype. A significant
number of patients already have ocular complications at
time of diagnosis of uveitis. JIA-associated uveitis carries
significant ocular morbidity that can progress into adult-
hood. Treatment with immunosuppressive agents can
reduce the risk of ocular complications. Although con-
trolled clinical trials are under way to assess the efficacy
of biologic agents in JIA-associated uveitis, therapies
with these agents seem to have encouraging results.
Aims
To evaluate the efficacy of the treatment of refractory
uveitis with tumor necrosis factor antagonist (TNF) in a
Pediatric Rheumatology Centre.
Methods
We reviewed the case notes of patients followed in our
outpatient clinic, diagnosed with uveitis that are being
actively treated with biological agents.
Results
Five patients: four had JIA (two with the seronegative
polyarticular subtype, one persistent oligoarticular, one
systemic JIA) and one had chronic idiopathic uveitis.
The mean age of these patients was 12.6±7.4 years old,
the mean disease duration was of 4.8±1.1 years and the
mean disease duration at the beginning of the biological
treatment was of 2.2±1.6 years. All the patients were
treated with anti-TNF agents with a mean duration of
26.4±19.2 months: three patients with infliximab and
two with etanercept. Only one child was switched from
etanercept to infliximab due to therapy failure. The con-
comitant immunosuppressive therapy in all the patients
was reduced and only one patient remained on addi-
tional prednisolone (10 mg/day). No serious adverse
events were registered.
Conclusion
Our case series provides evidence that successful out-
comes may be achieved with biological immunosuppres-
sive therapy, although clinical trials are required to
define the real efficacy of this strategy.
Published: 14 September 2011
doi:10.1186/1546-0096-9-S1-P64
Cite this article as: Campanilho-Marques et al.: Off-label use of biological
agents in the management of uveitis: experience from a pediatric
rheumatology centre. Pediatric Rheumatology 2011 9(Suppl 1):P64.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Campanilho-Marques et al. Pediatric Rheumatology 2011, 9(Suppl 1):P64
http://www.ped-rheum.com/content/9/S1/P64
© 2011 Campanilho-Marques et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
